Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study of the Distance between the Base of the Vermiform Appendix and the Ileocaecal Junction in Bangladeshi People of Different Age and Sex Groups.

Mymensingh medical journal : MMJ·2026
Same author

Copper restriction unmasks axonal degeneration in a mouse model of X-linked hereditary motor neuropathy.

Metallomics : integrated biometal science·2026
Same author

Exploring AACA Members' Perceptions of Integrating Technologies in Anatomy Education.

Clinical anatomy (New York, N.Y.)·2026
Same author

Shorter residual inferior mesenteric artery stump length on objective CT measurement is associated with improved oncological outcomes in rectal cancer surgery: A propensity score matched analysis.

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland·2025
Same author

From epigenetic alterations to clinical impact: the role of DNMT3A in modulating immunotherapy response.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Clinical presentation, MR imaging and outcome in children with myelin oligodendrocyte glycoprotein antibody-negative acute disseminated encephalomyelitis.

European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society·2025

Related Experiment Video

Updated: Jul 17, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.

C Gneiss1, P Tripp, F Reichartseder

  • 1Clinical Department of Neurology, Innsbruck Medical University, 6020 Innsbruck, Austria.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|February 1, 2007
PubMed
Summary

Neutralizing antibodies (NAb) can reduce the effectiveness of interferon beta (IFNbeta) therapy for multiple sclerosis (MS). Intramuscular IFNbeta-1a showed a lower NAb frequency compared to other forms, suggesting differences in immunogenicity.

More Related Videos

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
06:03

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

Published on: September 20, 2024

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Related Experiment Videos

Last Updated: Jul 17, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens
06:03

Whole Blood Assay with Dual Co-Stimulation for Antigen-Specific Analysis of Host Immunity to Fungal and Viral Pathogens

Published on: September 20, 2024

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Area of Science:

  • Immunology
  • Neuroimmunology
  • Pharmacology

Background:

  • Interferon beta (IFNbeta) is a crucial first-line treatment for multiple sclerosis (MS).
  • Development of anti-IFNbeta neutralizing antibodies (NAb) can lead to reduced treatment efficacy in some MS patients.
  • Understanding the immunogenicity of different IFNbeta formulations is essential for optimizing MS management.

Purpose of the Study:

  • To investigate the cross-sectional frequency of NAb in MS patients receiving different IFNbeta formulations.
  • To compare the prevalence of binding antibodies (BAb) and NAb across IFNbeta-1b, IFNbeta-1a intramuscular (im), and IFNbeta-1a subcutaneous (sc) treatments.
  • To analyze NAb titers and their relationship with BAb positivity across treatment groups.

Main Methods:

  • Cross-sectional study involving 846 MS patients treated with IFNbeta-1b, IFNbeta-1a im, or IFNbeta-1a sc.
  • Measurement of anti-IFNbeta neutralizing antibodies (NAb) in all patients.
  • Measurement of anti-IFNbeta binding antibodies (BAb) in 808 patients.
  • Statistical analysis to compare antibody frequencies, proportions, and titers between treatment groups.

Main Results:

  • The frequency of NAb was significantly lower in patients receiving IFNbeta-1a im (5%) compared to other IFNbeta forms (22-35%).
  • Binding antibody (BAb) frequencies varied significantly, from 45% (IFNbeta-1a im) to 88% (IFNbeta-1b).
  • The proportion of NAb-positive patients within the BAb-positive group was lowest for IFNbeta-1a im (12%) and highest for IFNbeta-1a sc (51%).
  • Median NAb titers were higher in IFNbeta-1a-treated patients than in IFNbeta-1b-treated patients.
  • A higher frequency of NAb titers > 100 NU/mL was observed in IFNbeta-1a-treated patients compared to IFNbeta-1b-treated patients.

Conclusions:

  • IFNbeta-1a im demonstrates a lower immunogenic profile regarding NAb development compared to other IFNbeta formulations.
  • Significant differences in BAb and NAb prevalence exist across various IFNbeta preparations used for MS treatment.
  • These findings provide valuable insights into the comparative immunogenicity of different IFNbeta therapies, aiding in clinical decision-making for MS patients.